Alpha Cognition Inc. (ACOG)

NASDAQ: ACOG · Real-Time Price · USD

6.10

-0.33 (-5.13%)

Apr 28, 2026, 2:30 PM EDT - Market open

-5.13% (1D)

Market Cap	132.82M
Revenue (ttm)	10.22M
Net Income (ttm)	-20.67M
Shares Out	21.77M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,136
Open	6.45
Previous Close	6.43
Day's Range	5.98 - 6.78
52-Week Range	4.50 - 11.54
Beta	2.52
Analysts	Strong Buy
Price Target	16.00 (+162.3%)
Earnings Date	May 14, 2026

About ACOG

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the trea... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Country Canada

Stock Exchange NASDAQ

Ticker Symbol ACOG

Website https://www.alphacognition.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ACOG stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 162.30% from the latest price.

Price Target

$16.0

(162.30% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therape...

1 day ago - Business Wire

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for ...

7 days ago - Business Wire

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeu...

12 days ago - Business Wire

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

26 days ago - Business Wire

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition exited ...

27 days ago - Newsfile Corp

Alpha Cognition Earnings Call Transcript: Q4 2025

ZUNVEYL adoption accelerated in Q4 2025, with strong sales growth, expanding prescriber base, and improved payer access. The company remains well-funded, expects continued growth in 2026, and is advancing key clinical studies to further differentiate its product.

4 weeks ago - Transcripts

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeu...

4 weeks ago - Business Wire

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...

6 weeks ago - Business Wire

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on devel...

7 weeks ago - Business Wire

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated ...

2 months ago - Business Wire

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a biopharmaceutical company focused on developing nov...

2 months ago - Business Wire

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (the “Company”, “we”, “us” and “ours”) (NASDAQ: ACOG), a commercial-stage neuroscience company focused on advanci...

3 months ago - Business Wire

Alpha Cognition Transcript: Fireside Chat

The discussion highlighted ZUNVEYL's commercial progress in the long-term care Alzheimer's market, with expanding payer coverage, robust clinical trial plans, and new formulations targeting unmet needs. Key catalysts include inflection in sales by mid-2026, international approvals, and pivotal trial data.

5 months ago - Transcripts

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing ther...

5 months ago - Business Wire

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Dallas, Texas--(Newsfile Corp. - November 14, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition com...

5 months ago - Newsfile Corp

Alpha Cognition Earnings Call Transcript: Q3 2025

Q3 2025 saw robust ZUNVEYL sales growth, expanded long-term care engagement, and improved financials, with a strengthened balance sheet and reduced expense guidance. Market access and prescriber adoption accelerated, supported by new studies and strategic pricing actions.

5 months ago - Transcripts

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”) today announced its financial results for the third quarter en...